Clinical trials: ER Positive Breast Cancer
Metastatic Breast Cancer, Estrogen Receptor Positive Tumor
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of efficacy and tolerability for patients who have…
- Conditions
- Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
- Trial name
- FLAG (NCT01266213)
- Testing
- Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Samsung Medical Center
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Breast Cancer
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899639
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
This phase II trial studies the side effects and how well letrozole and imatinib mesylate work in treating postmenopausal participants with estrogen or progesterone positive breast cancer that has spread to other places in the…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive
- Trial name
- NCT00338728
- Testing
- Imatinib Mesylate, Letrozole
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Musculoskeletal Complications
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone…
- Conditions
- Breast Cancer, Musculoskeletal Complications, Pain
- Trial name
- NCT01598298
- Testing
- duloxetine hydrochloride
- Where
- 714 sites in United States
- Volunteers
- 299 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
- Trial name
- NCT00255463
- Testing
- Anastrazole, Gefitinib
- Where
- 34 sites in Czechia, France and 5 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
Breast Cancer
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002967
- Testing
- cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate
- Where
- 108 sites in United States, Canada
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
Preclinical data has demonstrated that entinostat (SNDX-275) can enhance fulvestrant sensitivity in hormone receptor-positive breast cancer in animal models.
- Trial name
- ENCORE305 (NCT02115594)
- Testing
- Fulvestrant, Entinostat
- Where
- United States
- Sponsor
- Syndax Pharmaceuticals
Breast Cancer
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897065
- Testing
- microarray analysis, polymerase chain reaction, protein expression analysis
- Where
- United States
- Volunteers
- 957 people
- Sponsor
- Massachusetts General Hospital
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Breast Cancer
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old…
- Trial name
- NCT01712893
- Testing
- Zoladex
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Fudan University
Breast Cancer
Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors.
The aim of this pilot study is to assess the change in pain, measured with the Modified Brief Pain Inventory - Short Form (mBPI-sf), at 4, 8, and 12 weeks.
- Trial name
- DOLFLEX (NCT07199556)
- Testing
- Food supplement
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Arafarma Group, S.A.
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01385280
- Testing
- therapeutic estradiol, exemestane, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Arizona
Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
This phase IIb trial studies how well alternative dosing of exemestane before surgery works in treating in postmenopausal patients with stage 0-II estrogen positive breast cancer.
- Conditions
- Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02598557
- Testing
- Exemestane, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States, Italy
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01409811
- Testing
- zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
The primary objective of this trial is to evaluate the effect of the addition of a 2 year, centrally delivered individualized, telephone-based lifestyle intervention focusing on weight management to a mailed educational…
- Trial name
- LISA (NCT00463489)
- Testing
- Lifestyle intervention, Mail-based
- Where
- 21 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer, Early Stage Estrogen Receptor (ER) Positive Breast Cancer
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer
Investigators will examine the impact of the Breast Cancer Index (BCI) result on patients' anxiety / fear of recurrence and satisfaction with decisions regarding endocrine therapy.
- Trial name
- NCT02057029
- Testing
- BCI Assay Results
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Yale University